REG - Aptamer Group PLC - Notice of Results and Investor Presentation

AptamerAnnouncement

08/11/2023 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231108:nRSH8132Sa&default-theme=true

RNS Number : 8132S  Aptamer Group PLC  08 November 2023

8 November 2023

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Notice of Results and Investor Presentation

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, will announce its full year
results for the year ended 30 June 2023 on Thursday 9 November 2023.

The Company is pleased to announce that Dr Arron Tolley (Chief Technical
Officer), Dr David Bunka (Chief Scientific Officer), and Andrew Rapson (Chief
Financial Officer) will provide a live presentation relating to the Final
Results via Investor Meet Company on Thursday 9 November 2023 at 3:00pm GMT.

The presentation is open to all existing and potential shareholders. Questions
can be submitted at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet
Aptamer Group, via:
https://www.investormeetcompany.com/aptamer-group-plc/register-investor

Investors who already follow Aptamer Group on the Investor Meet Company
platform will automatically be invited.

 

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Steve Hull
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) Group develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer(®)
platform.

Optimer(®) binders are oligonucleotide affinity ligands that can function as
an antibody alternative. The global affinity ligand market is currently worth
over $170 billion. Optimer(®) binders are engineered to address many of the
issues found with alternative affinity molecules, such as antibodies, and
offer new, innovative solutions to bioprocessing, diagnostic and
pharmaceutical scientists.

Aptamer has successfully delivered projects for global pharma companies,
diagnostic development companies and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer(®) technology and processes, scientists
and collaborators can make faster, more informed decisions that support
discovery and development across the Life Sciences.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBPBTTMTBMBPJ